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ABSTRACT

DNA methylation is an epigenetic modification that can alter gene expression
without a DNA sequence change. The role of DNA methylation in biological processes
and human health is important to understand, with many studies identifying associations
between specific methylation patterns and diseases such as cancer. In mammals, DNA
methylation almost always occurs when a methyl group attaches to a cytosine followed by
a guanine (i.e. CpG dinucleotides) on the DNA sequence. Many statistical methods have
been developed to test for a difference in DNA methylation levels between groups (e.g.
healthy vs disease) at individual cytosines. Site level testing is often followed by a post hoc
aggregation procedure that explores regional differences. Although analyzing CpGs
individually provides useful information, there are both biological and statistical reasons
to test entire genomic regions for differential methylation. The individual loci may be noisy
but the overall regions tend to be informative. Also, the biological function of regions is
better studied and are more correlated to gene expression, so the interpretation of results
will be more meaningful for region-level tests. This study focuses on developing two
techniques, functional principal component analysis (FPCA) and smoothed functional
principal component analysis (SFPCA), to identify differentially methylated regions
(DMRs) that will enable discovery of epigenomic structural variations in NGS data. Using
real and simulated data, the performance of these novel approaches are compared with an
alternative method (M3D) for region level testing.
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1. INTRODUCTION

1.1. BASICS OF GENETICS
The field of genetics involves the study of heredity and genetic variation, which
includes investigating the properties of genes. Genes are sections of deoxyribonucleic acid
(DNA) located inside each cell of an organism that encode proteins and play a role in
determining the nature of living organisms 1. Organisms inherit phenotypic traits or
characteristics based on the genes transmitted by their parents. For example, the products
of sexual reproduction often resemble their parents because they have inherited half of their
genetic material from each parent. Investigating the function of genes at the molecular level
is part of field a known as molecular genetics, which combines genetics with molecular
biology. The Central Dogma of Molecular Biology2 offers a way to understand how genes
are converted to functional information. The Central Dogma describes how genes are
transcribed to messenger RNA (the transcriptome) that is translated to proteins, which
mediate most of the cell’s biochemical functions (the proteome). Thus, molecular genetics
involves not only inheritance but how genes are expressed, which controls how much of
specific proteins are produced at the cellular level and can ultimately affect phenotypes.
Many phenotypic traits are complex in nature as they may be determined by multiple genes
and also influenced by the environment 1, 2.

1.2. GENOMICS
The field of genomics involves the study of the complete set of deoxyribonucleic
acid (DNA) in an organism (i.e., the genome) 2. The mapping of genomes for particular

2
organisms enables better understanding of the location of genes and their functions on a
large scale. The human genome is the complete sequence of genetic information in humans,
which is stored in each cell’s nucleus and mitochondria. Genetic information is encoded in
the DNA molecule and is stored on structures called chromosomes (Figure 1.1). DNA is
double-stranded and is comprised of millions of nucleotides, organic molecules that
function as subunits and are composed of a nitrogen nucleobase (i.e., guanine (G), adenine
(A), thymine (T), and cytosine (C)), a five-carbon sugar, and at least one phosphate group
3

. DNA can be annotated into important substructures such as protein-coding genes and

non-coding sequences (Figure 1.1). These main structures can be further annotated into
substructures such as exons, introns, CpG islands, and promoter regions that play specific
roles in different molecular processes 4.

Figure 1.1. Location and Structure of the DNA Molecule in the Human Genome. Figure
obtained from 5.

3
The first genome-wide DNA sequence in humans, with a total of about three billion
nucleotide positions, was completed by the Human Genome Project

6

in 2001. DNA

sequencing determines the order of all the nucleotides for any particular organism. This
sequence information was initially used in organism specific genome projects, combined
with computational methods and domain expertise, to map the location of genes and other
substructures, to be used as reference for future studies of that organism. With advances in
technology, all of the genetic information from any individual can now be revealed using
whole-genome sequencing 7. Such genome-wide studies are powerful tools for exploring
genetic contributions to phenotypic variation and have the potential to allow for important
health advances, such as personalized medicine, in the future.

1.3. EPIGENETICS
Epigenetics refers to heritable changes in genetic activity and expression that take
place without any change in the DNA sequence. The word “epigenetics” comes from the
Latin “epi,” which means “above” or “on top of” the genetic information. Epigenetics
encompasses all the information that is contained in the cell and expressed for more than
one cell generation, as the DNA sequence remains stable 8. In other words, epigenetics is
“the study of mitotically heritable changes in gene function that cannot be explained by
changes in DNA sequence” 9. DNA methylation and histone modifications, which involve
the addition of chemical marks to the DNA or histone proteins, are two key epigenetic
mechanisms (Figure 1.2) 10. DNA methylation occurs when a methyl (Me) group attaches
to a cytosine (C) base on the DNA molecule. Histone modifications occur when certain
chemical groups (e.g. methyl, acetyl) attach to the tails of histone proteins. Epigenetic

4
modifications help to regulate gene expression
with cancer

14, 15

and other diseases

16-17

11-13

and epigenetic aberrations correlate

. Environmental factors can affect epigenetic

mechanisms. An advantage of this environmental influence is that drugs can be formulated
to modify epigenetic patterns in cancer cells 18.

Figure 1.2. Two key epigenetic modifications: (1) DNA methylation and (2) histone
modification. Figure obtained from Qiu (2006) 19.
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1.4. DNA METHYLATION
The four DNA nucleotides (adenine (A), cytosine (C), guanine (G), and thymine
(T)) can be categorized into two classes, the pyrimidine-based nucleotides (C and T) and
the purine-based nucleotides (G and A). On the double stranded DNA (dsDNA) a purine
on one strand pairs with a pyrimidine on the other strand. Called complementary base
pairing, this always occurs where A is paired with T while G is paired with C. The A/T
pairing is secured by two hydrogen bonds, but the G/C pairing is mediated by three,
creating a stronger bond

20

. The length of the dsDNA is measured by the number of

nucleotide base pairs (bp), which ranges from a few thousand (i.e., kilo base pairs (kbp))
in single-celled organisms to several million (i.e., mega base pairs (Mbp)) per molecule for
complex organisms 21.
DNA methylation occurs in most organisms, but not in the budding yeast,
Saccharomyces cerevisiae, and the nematode worm, Caenorhabditis elegans. It is also
limited to embryonic development in the fruit fly, Drosophila melanogaster

22, 23

. In

mammals, DNA methylation usually takes place when cytosine (C) is followed by guanine
(G) in the 5′ − 3′ direction of the DNA sequence. This is denoted as CG or CpG, the latter
notation showing that cytosine and guanine are connected by a phosphate on one of the
DNA strands 24. In plants, DNA is methylated in three sequence contexts: CG, CHG and
CHH (where H = A, T or C). At least three DNA methylation pathways exist in plants and
each pathway appears to methylate cytosines in different sequence contexts 25.
In mammals, DNA methylation occurs as the result of a family of de novo DNA
methyltransferase enzymes (DNMT3) and is maintained during DNA replication by a
maintenance DNA methyltransferase (DNMT1)

26

. Plants also have methyltransferase
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enzymes, some similar to DNMT1 and other unique to plants 25. At some locations, known
as CpG islands, the number of CpG sites in relation to the CG content in a sequence of a
particular length is higher than expected. CpG islands occur upstream of many genes and
are usually unmethylated 25. Recent research suggests that the relationship between genetic
variation, DNA methylation, and expression is complex 27.
DNA methylation plays a key role in many biological processes, including genomic
imprinting, X-chromosome inactivation, embryonic development, and the silencing of
transposable elements 22, 28-31. In plants, DNA methylation is essential for genome stability
and plant development

28, 31

. In humans, specific DNA methylation patterns have been

associated with the development of cancer

14

. An overall loss of DNA methylation

(hypomethylation) that occurs with a gain in methylation (hypermethylation) at the CpG
islands in promoter regions is often found in cancer cells 14, 17.

1.5. NEXT-GENERATION SEQUENCING TECHNOLOGY
The introduction of next-generation sequencing (NGS) technology (also known as
high-throughput sequencing) in the 2000s enabled researchers to conduct genome-wide
investigations of many different molecular level phenomena, including gene expression
and epigenetic modifications such as DNA methylation. NGS is a high-throughput
technology that allows cost-effective processing of millions of sequencing reads in parallel
32

. Although several companies manufacture NGS technologies (e.g. Illumina, Roche 454,

Life Technologies), there is a set of general processing steps shared between them even
though their specific technical details may differ (Figure 1.3) 33.
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Figure 1.3 Next generation sequencing processing steps for platforms requiring clonally
amplified templates (Roche 454, Illumina, and Life Technologies). Input DNA is
converted to a sequencing library by fragmentation, end repair, and ligation to platform
specific oligonucleotide adapters. Individual library fragments are clonally amplified by
either (1) water in oil bead– based emulsion PCR (Roche 454 and Life Technologies)
or (2) solid surface bridge amplification (Illumina). Flow cell sequencing of clonal
templates generates luminescent or fluorescent images that are algorithmically
processed into sequence reads. These reads are then aligned to a reference genome and
evaluated based on the biological mechanism being investigated. Figure modified from
Voelkerding et al. (2010) 33.

NGS enables the cost-efficient generation of large sequencing data sets based on
whole genomes at single-base resolution. Today, NGS is used for variant detection by
resequencing (personnel genomes), transcriptome analysis (RNA-seq), and the discovery
of epigenetic variations (DNA methylation)

34

. NGS methods offer advantages for such

large-scale studies over the traditional Sanger sequencing developed in 1977. The NGS
high-throughput platforms have a higher coverage giving a more reliable and accurate
result compared to those obtained via Sanger Sequencing technology 34. Coverage is one
of the common measures of the amount of sequence data generated and it refers to the
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average number of times each base in the genome is sequenced 32. In addition, the nextgeneration sequencing platforms are able to detect methylation levels at individual
cytosines due to their higher accuracy and sensitivity, making them suitable for epigenomic
investigations.

1.6. GENOME-WIDE METHYLATION PROFILING APPROACHES
DNA methylation can be investigated at a genome-wide level using a variety of
technologies, most notably microarrays and next-generation sequencing (NGS). The focus
of this work is on NGS technologies as they can cover cytosine sites across the entire
genome and not just a pre-chosen subset covered by microarrays. NGS entails a series of
steps as described in section 1.5, including library preparation, amplification, sequencing,
imaging, and alignment, resulting in millions of sequencing reads per run

33

. An

improvement over microarray technologies, next-generation technologies can cover a wide
breadth of the genome including repetitive elements 35. Along with these newer sequencing
technologies, novel approaches have been developed to obtain genome-wide profiles of
DNA methylation. Some require bisulfite-converted genomic DNA for template
preparation, such as MethylC-seq and RRBS (reduced representation bisulfite sequencing)
35, 36

; some rely on the enrichment of methylated DNA, such as MeDIP-seq (methylated

DNA immunoprecipitation sequencing) and MBD-seq (methylated DNA binding domain
sequencing)

37, 38

; and some use methylation-sensitive characteristics of restriction

enzymes to digest genomic DNA 38. Each method has advantages and disadvantages with
regard to covered regions, sequencing depth, accuracy, and cost. For example, MeDIP-seq
and MBD-seq cannot investigate at a single-base resolution, but they can reflect high-to-
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medium methylation of DNA sequences covering broader regions

22

. In contrast, whole

genome bisulfite-based methods such as methylC-seq provide measurements at single
cytosines and are considered the gold standard, but the cost is still too high for many
smaller-scale labs to utilize this technique 23. As a compromise, RRBS combines the use
of restriction enzymes with bisulfite sequencing and NGS to obtain methylation levels at
individual cytosines in a subset of the genome with high CpG content. This reduces the
cost at the expense of losing information in some regions. The focus on the methods
developed in this work are on the bisulfite based methods, described in more details in next
section.

1.7. BISULFITE SEQUENCING-BASED METHODS TO PROFILE DNA
METHYLATION
Using NGS to quantify DNA methylation at the single based level relies on a
technique called bisulfite sequencing

39

. This technique utilize a process called bisulfite

conversion of genomic DNA, in which the DNA molecules undergo a bisulfite treatment
that allows methylated and unmethylated cytosines to be differentiated at single-base
resolution. Using this method, unmethylated cytosines are converted to uracils (which will
be read as thymines by the DNA polymerase), leaving methylated cytosines unmodified 39.
When the bisulfite-treated DNA is amplified by a polymerase chain reaction (PCR), it
yields products in which unmethylated cytosines appear as thymines (Figure 1.4).
Therefore, when combined with NGS, it is possible to infer the number of cytosine and
thymine reads at a specific genomic position of a known cytosine site. This results in a
count of the number of methylated reads and unmethylated reads at single-base resolution
which could be converted to a methylation percentages at that position.
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1.8. REDUCED REPRESENTATION BISULFITE SEQUENCING
Bisulfite sequencing can be combined with NGS for whole genome studies using
methods such as BS-seq or methylC-seq

40

. Although these are considered the gold

standard, they are often cost prohibitive, especially for large genomes, large sample sizes,
and small labs. A smaller-scale method developed by Meissner et al.

36

also employs

bisulfite-converted DNA and provides insights into a subset of the methylome 41. Meissner
et al. 36 pioneered the reduced representation bisulfite sequencing (RRBS) approach, which
is more feasible for case-control studies in humans with large sample sizes 42 and for use
in smaller labs. RRBS digests genomic DNA with a methylation-insensitive restriction
enzyme, where fragments of a specific length are used to filter the most informative
genomic subset. Then, a bisulfite conversion of the fragments is undertaken to establish
DNA methylation levels

45

, which ultimately provides DNA methylation patterns in the

chosen segments of the genome. These restricted fragments often cover core promoters and
CpG islands

41

, which contain key regulatory parts of the genome. Altogether, RRBS

comprises only ~1% of the underlying whole genome

41

. DNA quantities as little as 10-

300 ηg are sufficient to produce accurate DNA methylation levels with RRBS

43

.

Therefore, RRBS is suitable for many clinical samples (e.g., tumors) that only supply a
small quantity of genomic input DNA material. The following section describes selected
steps in preparing an RRBS library (see Figure 1.4).
The first step is to isolate the genomic DNA. Using highly purified genomic input
DNA is mandatory when generating a high-quality RRBS library

43

. Otherwise,

contaminated DNA molecules might interact with the restriction enzymes, which affect the
bisulfite conversion 43. The second step is the digestion reaction and fragmentation.
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Figure 1.4. Workflow of a RRBS Library Preparation. Image Courtesy of Olbricht (2006)
44
.
Two commercially available enzymes, MspI and TaqI, 43 can be used since they are
insensitive to CpG DNA methylation, and will thus not bias the methylation measurements.
However, only MspI produces fragments that contain CpG dinucleotides, at both ends,
which is important to aid in capturing CpG dense regions while reducing the genomic
space. One disadvantage of MspI is that a methylated cytosine in the first position of the
restriction motif C↓CGG hampers the digestion reaction 43.
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Some intermediate steps are then taken to prepare the fragments remaining after
the restriction enzyme digestion for sequencing. Methylation adapters are ligated to double
stranded sheared DNA fragments so that the fragments can be hybridized to the flow cell
for sequencing 45.
Using RRBS libraries, both single-end and paired-end sequencing can be
conducted, but adapters must be methylated cytosines to maintain compatibility with the
subsequent bisulfite conversion. One advantage of paired-end sequencing is that it
improves the mapping efficiency by fostering unique alignments. However, it can also
produce inaccurate DNA methylation levels because overlapping pairs produce redundant
DNA methylation information

46

. Before sequencing, fragments are size selected where

fragments that do not meet a minimum length are filtered out before the remaining
fragments are bisulfite converted. It has been shown through in silico analyses that a size
selection for fragments of 40-220 bp that contains the MspI restriction motif C↓CGG
covers the preparation of most promoter sequences and CpG islands 47.
In the third main step, the digested and size-selected fragments are bisulfite
converted as described in section 1.7 and then amplified by PCR. Step four involves
sequencing the bisulfite converted fragments using a NGS platform. At this time, RRBS
has only been performed on Illumina platforms 46. In step five, sequenced reads are aligned
to a reference genome. Finally, in step six, the methylation status of each cytosine is
determined for all reads and summarized, resulting in a count of the number of methylated
and the number of unmethylated reads at each cytosine sequenced. Note that in mammals,
typically only CpG sites are summarized, but all cytosines are of interest in plant
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1.9. LITERATURE REVIEW FOR STATISTICAL METHODS
Table 1.1 provides information about various statistical methodologies used to discover
individual differentially methylated CpG sites and differentially methylated regions for
bisulfite-based NGS technology. Note that some methods were utilized for whole genome
bisulfite sequencing studies such as BS-seq 48, while other were only tested on RRBS data. Both
methods yield data with counts of both methylated and unmethylated reads at each cytosine site
where data are available. At times, researchers may want to relate individual CpG sites to a
particular phenotype

49

. Early BS-seq studies typically profiled cell lines, but did not collect

replicates, and used the Fisher’s exact test (FET) to define differentially methylated cytosine
sites between phenotypic conditions 50. This strategy may be adequate for comparing cell lines,
but overall, the use of FET should be avoided because FET does not take into account inherent
biological variations. As such, when using FET in a two-condition comparison, the data must
be condensed to account for each condition, meaning that any within-condition variability is
disregarded. Because this process underestimates variability and magnifies differences, the
false positive rate is much higher. Similarly, using a binomial distribution (e.g., within a logistic
regression framework, such as methylKit

51

) does not enable an accurate estimation of

biological variability without using an over-dispersion term. Therefore, the optimal statistical
model for measuring replicated BS-seq

48

DNA methylation is a beta-binomial. Based on the

methylation proportion at any given site, the observations are binomially distributed, while the
methylation proportion can vary across experimental units (e.g., patients), in a beta distribution.
This is advantage can be seen in the latest versions of the BiSeq 48 and methylSig 52 methods,
which employ beta-binomial assumptions.
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Table 1.1 Statistical Methods to Detect Differentially Methylated Loci or Regions
Methods

Designed for

BSmooth
BiSeq
MethylKit
MethylSig

BS-seq
BS-seq
BS-seq
BS-seq

MAGI
M3D

BS-seq
RRBS

Determines regions Accounts for
covariates
or uses predefined

Determines
Determines
Predefined
Determines
Predefined
Predefined

No
Yes
Yes
No
No
Yes

Statistical elements

Bump hunting on smoothed t-score
Beta-binomial (Wald test)
Logistic regression
Beta-binomial (Likelihood-Ratio
Test)
FET and logistic regression
Kernel-based

Although site level tests can be informative, differentially methylated regions
(DMRs) have a greater ability to predict phenotypes 53. Another advantage of using DMRs
is that although differences at any given site may be small and noisy, variations across a
region can often be more easily detected since neighboring methylation levels are typically
highly correlated 54. However, methods operating on predefined regions differ from those
that define regions of differential methylation after site level testing (i.e., the regions are
not known in advance). Although the false discovery rate (FDR) needs to be controlled
across the regions tested in both cases, this is nontrivial when the regions are not known in
advance, making this strategy much more difficult for controlling the false positives. When
the region is undefined prior testing, it is impossible to extrapolate the region-level FDR
control from the site-level tests 53. As such, the best approach is to use predefined regions
which can be defined based on annotation regions (e.g., CpG islands, CpG shores, exons,
or introns), or defined based on non-annotation regions that are defined based on CpG
density. These non-annotation based CpG clusters can be defined as follows: (1) CpG sites
that covered at least 75% of samples are defined as frequently covered CpG sites, and (2)
a maximum distance of 100 base pairs to the nearest neighbor within a region is accepted.
The predefined regions are limited to regions with at least 20 frequently covered CpG sites
50

.
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At the region-level, there are several statistical methods that can be employed, such
as methylSig

52

, methylKit

51

, and others. Of the approaches that determine the regions

after site-level testing, BSmooth is a widely cited package that looks for runs of smoothed,
absolute t-like scores beyond a threshold. However, this approach does not contain a
permutation strategy to control region-level FDR. Because DNA methylation levels
usually have a strong spatial correlation, if such correlations could be accounted for in a
region level testing procedure, the statistical power of that approach would increase greatly.
Interestingly, M3D 55 has proposed such a nonparametric statistical test that would detect
DMRs from predefined regions based on CpG density, while also accounting for spatial
correlation. This method uses a radial basis function (RBF) kernel function to derive the
Maximum Mean Discrepancy (MMD) between the data sets to assess the homogeneity of
the underlying methylation distribution. MAGI

56

characterizes testing regions using

existing annotation information, assuming spatial homogeneity across regions, but does
not adjust for spatial correlations between individual cytosine sites. There are two versions
of MAGI for site level and region level tests. Each version has the option of a FET if
replicates are not available or a logistic regression when replication is present. The first
version (MAGIc ) tests for differences between methylation levels at individual cytosine
sites within each annotated region. The second version (MAGIg ) is comprised of two steps:
(1) using an a priori threshold to classify each cytosine as either methylated or
unmethylated, and, (2) performing a single FET or logistic regression on the resulting data
for each region, with the assumption that the resulting data are binomially distributed 56.
This dissertation focuses on developing methods for DMR testing over predefined
regions based on CpG density. Functional data analysis techniques are employed to more
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fully utilize the nature of correlated methylation levels over genomic regions. Two
techniques, functional principal component analysis (FPCA) and smoothed functional
principal component analysis (SFPCA), are proposed to identify differentially methylated
regions (DMRs) that will enable discovery of epigenomic structural variations in NGS data.
The performance of these novel approaches are compared with the only other method
(M3D) that investigates shape changes over a predefined region.

1.10. INTRODUCTION TO FUNCTIONAL DATA ANALYSIS
The main idea of functional data analysis (FDA) 57 involves analyzing data that can
be represented as curves or functions. Typically, a trajectory of data is collected on one or
more individuals of the form (𝑡𝑖 , 𝑦𝑖 ) where 𝑦𝑖 represents the quantity of interest at time or
position𝑡𝑖 . Although these observations are collected at discrete points, the idea behind
FDA is that there is underlying function 𝑥(𝑡) that is smooth such that data at sequential
points 𝑦𝑖−1 , 𝑦𝑖 , 𝑦𝑖+1 are linked to each other in some way and likely to exhibit similarity.
This smoothness property is important for functional data, as otherwise wise it could be
treated as multivariate data. One or more derivatives of the function 𝑥(𝑡) is assumed to
exist due to the smoothness, where 𝐷𝑚 𝑥(𝑡) indicates the derivative of order 𝑚 at
argument 𝑡. Studying these derivatives of the function allows the exploration of properties
such as velocity and acceleration.
To estimate the function 𝑥(𝑡) and certain number of its derivatives, the discrete
data 𝑦𝑖 are typically utilized 57. However, the data observed may not be smooth due noise
or measurement error. When the signal-to-noise ratio is low or sparsely sampled, it is
helpful to have data from a random sample of individual records so that information can
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be drawn from similar trajectories to obtain a more stable estimate of a specific curve. In
functional data analysis, the goal is to represent experimental data collected over time or
space with a series linear combinations of basis functions that are mathematically
independent 60.
A function 𝑋(𝑡) can be represented as 𝑋(𝑡) = ∑𝐾
𝑗=1 𝐶𝑗 𝜙𝑗 (𝑡)=𝝓(𝒕)𝑪 with 𝐾 known
basis functions 𝜙𝑗 (𝑡) and 𝐶1 , … , 𝐶𝐾 are coefficients to be estimated. 𝜙𝑗 are a set of basis
functions that are mathematically independent and have the property that they can
approximate any function well by taking a linear combination of a sufficient number 𝐾 of
these functions. Commonly used basis functions include the Fourier basis for periodic data
and the B-spline basis for non-periodic data 57.
The Fourier basis utilizes basis functions that represent sine and cosine functions
of increasing frequency. The Fourier basis expansion for periodic data is given as: 𝑥̂(𝑡) =
𝑐0 + 𝑐1 sin(𝜔𝑡) + 𝑐2 cos(𝜔𝑡) + 𝑐3 sin(2𝜔𝑡) + 𝑐4 cos(2𝜔𝑡) + ⋯.
The system is defined by basis functions: { 𝜙1 (𝑡) = sin(𝜔𝑡) , 𝜙2 (𝑡) =
cos(𝜔𝑡) , … , 𝜙2𝑘−1 (𝑡) = sin(𝑘𝜔𝑡) , 𝜙2𝑘 (𝑡) = sin(𝑘𝜔𝑡)} ,
constant 𝜔 =

2𝜋
𝑃

where

𝜙0 (𝑡) = 1,

the

, and 𝑃 is defined as the period of the first sine/cosine pair. If the values

of 𝑡𝑗 are equally spaced on the interval and the period of the function is equal to the length
of the interval, then the basis is orthogonal and computing the coefficients becomes easier,
especially in situation when the Fast Fourier Transformation (FFT) can be applied.
However, newer methods such as B-spline or wavelets can match or exceed this
computational efficiency 57.
The B-spline basis utilizes polynomial segments that are joined end-to-end such
that the segments are constrained to be smooth where they join. The points at which the
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segments join are called knots. Over each segment, a spline is a polynomial of order 𝑚
(order = degree+1). Polynomials in neighboring segments are required to have matching
derivatives up to order 𝑚-2 to impose smoothness. The number of basis functions will be
uniquely defined by the sum of the B-spline order and the number of interior knots. Without
interior knots, the spline becomes a simple polynomial. Note that with increasing order the
approximation of the function and its derivatives improve such that by order four, the fit is
very good

57

. B-Spline basis functions also have nice computational properties since the

inner product matrix of K basis functions is band structured. They are used when data are
not known to be periodic.

1.11. FDA FOR METHYLATION DATA
Since the methylation levels are often strongly correlated between CpG sites within
a region, it is natural to represent RRBS data as functional data that can be represented as
a linear combination of basis functions over a genomic region. This functional
representation allows the investigation of dominant modes of variation in the data. One
approach for this is functional principal component analysis (FPCA), where statistics are
calculated that summarize key features of the functions describing the curve of methylation
levels over a defined region and test for differences between conditions. In contrast, most
methylation studies to date either use statistics based on single CpG sites or summarize
single CpG values within a region of interest. In this work, statistical methods based on
FDA are developed for methylation data. Using simulated data, the utilities of FDA in the
context of methylation are explored and compared to other methods used in the literature.
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1.12. SUMMARY
The main purpose of this dissertation is to develop novel applications of functional
data analysis (FDA) procedures for DNA methylation data from RRBS studies.
Specifically, these FDA methods will enable testing for differentially methylated region
(DMRs) and pinpoint genomic regions that are likely to be biologically meaningful.
Testing differentially methylated regions through functional data analysis is described in
this dissertation for two papers: (1) Testing differentially methylated regions through
functional principal component analysis and (2) Smoothed functional principal component
analysis for detecting differentially methylated regions.
The first paper develops functional principal component analysis (FPCA) based on
Fourier and B-spline basis functions that successfully tests for differentially methylated
regions (DMRs) between two groups (e.g., case and controls) in RRBS data. An empirical
comparison, using a simulation based on real data, shows a significant increase in true
positive rates for detecting DMRs for the FPCA method in comparison with the M3D
approach. The FPCA method also shows considerable robustness with respect to coverage
depth and replication number.
The second paper develops a smoothed FPCA (SFPCA) for detecting DMRs by
combining a goodness-of-fit detecting with a roughness penalty to maintain the advantages
of basis expansion while improving the smoothness. The SFPCA method compares region
level differences in the average SFPCA scores between the cases and the controls. The
SFPCA scores take into account all information across all CpG sites in a genomic region,
capture summary information about dominant modes of variation in the methylation
profiles, and improve smoothness of estimated functional principal component curves. In

20
comparison to the M3D method, the SFPCA technique had substantially higher true
positive rates and was robust in relation to coverage depth and replications, using a
simulation based on real data.
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ABSTRACT
DNA methylation is an epigenetic modification that plays an important role in
many biological processes and diseases. Several statistical methods have been proposed to
test for DNA methylation differences between conditions at individual cytosine sites,
followed by a post hoc aggregation procedure to explore regional differences. While there
are benefits to analyzing CpGs individually, there are both biological and statistical reasons
to test entire genomic regions for differential methylation. Variability in methylation levels
measured by next-generation sequencing (NGS) is often observed across CpG sites in a
genomic region. Evaluating meaningful changes in regional level methylation profiles
between conditions over noisy site level measurements is often difficult to implement with
parametric models. To overcome these limitations, this study develops a nonparametric
approach, based on functional principal component analysis (FPCA), to detect predefined
differentially methylated regions (DMR). The performance of this approach is compared
with an alternative method (M3D), using real and simulated data.
Keywords: functional principal component; epigenomics; DNA methylation; nextgeneration sequencing
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1. INTRODUCTION
DNA methylation is an epigenetic modification involved in gene silencing and
tissue differentiation 1. The role of DNA methylation in human health has been heavily
researched in cancer studies as specific methylation patterns are associated with cancer 2.
Methylation can alter the function of genes by adding a methyl (CH3) group to DNA at
cytosine sites 3. In mammals, DNA methylation almost always occurs when a methyl group
attaches to a cytosine (C) when followed by a guanine (G) on the DNA sequence (i.e., CpG
dinucleotides) 3. A number of biological processes in mammals (e.g., the silencing of
transposable elements, gene expression regulation, genomic imprinting, and Xchromosome inactivation) involve methylation 4. Although the methylation of CpG
locations in promoter regions is linked to gene silencing, recent research indicates that CpG
methylation within genes bodies’ correlates with gene expression in a more complex
manner 5.
To obtain quantitative methylation data with base pair resolution across the
genome, a bisulfite treatment of DNA is followed by next-generation sequencing (NGS).
The bisulfite treatment transforms unmethylated cytosine (C) nucleotides into uracils (U),
which amplify as thymine (T) during a polymerase chain reaction (PCR) 6 while methylated
cytosines remain unchanged. The bisulfite treated sample is then sequenced via NGS to
obtain a library of sequencing reads. After sequencing reads derived from bisulfite treated
DNA are aligned to a reference genome, the methylation status of a cytosine in the
reference can be assessed by observing the aligned reads that overlap it. This means that
when a C in a bisulfite-treated read overlaps a cytosine in the reference, the reference
cytosine is methylated for that read 7. However, if a T in a bisulfite treated read overlaps

23
cytosine in the reference, then the reference cytosine is unmethylated for that read 7. This
approach can be applied to the whole genome using methylC-seq 8 or BS-seq 9 methods.
However, such studies are often costly for organisms with large genome sizes or for casecontrol studies where large sample sizes are needed. An alternative way to pair bisulfite
sequencing with NGS, called reduced representation bisulfite sequencing (RRBS)

10

,

focuses on capturing an informative subset of the genome. RRBS utilizes restriction
enzymes, such as MspI or TaqI, to cleave at CCGG loci so as to select an informative
subset of short reads to sequence

7

This process allows for more accurate and specific

results, with greater coverage of CpG-dense regions, including promotors, CpG islands,
and repetitive sequences. It reduces the numbers of nucleotides to be sequenced to 1% of
the genome and thus has a lower cost than sequencing all cytosines genome wide 7. Many
statistical issues are shared between whole genome methods and RRBS, but the following
discussion is in the context of RRBS for illustrative purposes.
An essential issue in DNA methylation analysis is identifying genomic loci or
regions with varying methylation levels related to distinct biological conditions. The
individual loci may be noisy (especially in heterochromatin) but the overall regions tend to
be informative 11. Region-level conclusions are also often more meaningful biologically,
making it desirable to consider summarizing information across individual loci in a region.
Recently, new statistical methods and software tools have been created to identify
differentially methylated regions (DMRs) from RRBS data

12-14

. Most of these methods

search for DMRs by first testing each cytosine site, then applying a post hoc aggregation
procedure. Post-hoc aggregation reflects the fact that it is unknown which regions are of
interest before testing, thus a procedure is needed to control the type I error rate while also
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letting the data guide the search for locations of informative regions. One of the first
methods developed, BSmooth 15, uses a smoothing process across the genome within each
sample to improve the accuracy when estimating the methylation level for any single CpG
site. This smoothing process is beneficial since methylation levels of neighboring cytosines
are known to be highly correlated

15

. BSmooth distinguishes differentially methylated

regions by combining neighboring differentially methylated cytosines (DMCs), which are
found using a t-statistic approach, with either a quantile or direct t-statistic cutoff 12. A
majority of the newer methods, such as BiSeq 16 and methylSig 17, also use local smoothing,
along with a beta binomial model of methylation at individual cytosine sites; these two
methods then combine the results of tests at individual loci to compute a measure of
significance for an estimated DMR. Another method called MethylKit

13

uses annotation

to provide a statistical test that pools the sequencing reads across an annotated unit (e.g.
gene) by group. The MethylKit approach is able to test at both the site level and for
predefined regions based on annotation. With multiple samples, a logistic regression with
a binary predictor corresponding to condition status is used, which can be expressed as a
binomial-based test 13.
In contrast, the MAGI

18

method tests directly for DMRs instead of computing

measures of significance for each region based on tests of individual cytosine sites. MAGI
assumes that methylation homogeneity exists within a predefined region, so no adjustments
are made for spatial correlations between cytosine sites. Methylation levels at each cytosine
site for each sample are labeled with a binary representation documenting whether or not
they exceed a specified decision boundary, with those exceeding the boundary declared
methylated and those falling below declared unmethylated. A Fisher’s Exact Test (FET) is
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then performed over each predefined region, counting the number of cytosine sites that
have changed states between groups

18

. A logistic regression is utilized in place of FET

when replicates are available.
A newer alternative approach, M3D 19, relies on the Maximum Mean Methylation
Discrepancy (M3D) method to assess changes in the shapes of methylation profiles within
the local predefined regions being tested. It applies a machine learning technique called
Maximum Mean Discrepancy (MMD)
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to test the homogeneity in underlying

methylation-generating distributions. The method uses a radial basis function (RBF) kernel
to construct the MMD between data sets under different conditions in each region being
tested; this number is modified based on changes in coverage profiles. The M3D statistics
are compared to a null distribution of observed M3D statistics between replicate pairs 19. It
has been suggested that the shape of the methylation profile is a crucial factor in predicting
gene expression, supporting the notion of a functional role for the methylation pattern 21.
In a review of the literature, it appears that only the M3D method considers differences in
the shape of the methylation profile over the region. The advantage of the M3D method is
based on a number of factors. First, the method is sensitive to spatially correlated changes
in methylation profiles. Second, the method explicitly accounts for difference in coverage
profiles between conditions. Thirdly, the method models inter-replicate variability along
the whole genome.
Building on the strengths of M3D, this research explores the use of functional data
analysis (FDA) techniques to characterize additional properties of the curve shapes of
methylation profiles in genomic regions. Since previous studies have indicated the
importance of methylation profile shape in predicting gene expression the FDA techniques
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could be advantageous in detecting the profiles that M3D is unable to find.
Specifically, in this research, a nonparametric approach based on functional principal
component analysis (FPCA) is introduced to detect differential methylation regions
(DMRs) from predefined regions, which explicitly accounts for adjusting spatial
correlations between cytosine sites. FPCA allows investigation of dominant modes of
variation in the RRBS data using the eigenfunctions of the methylation profile covariance
function. This method can be employed to test for changes in shape of methylation profiles
across regions, as opposed to testing only at individual cytosine sites. This study compares
the performance of FPCA to the only other existing method (M3D) that tests for region
level shape differences using a simulation based on real RRBS data.

2. METHODS
The computational procedure in this section follows the approach of DE-FPCA 22,
an approach that was developed for gene expression studies. DE-FPCA uses functional
principal component analysis (FPCA) to decompose gene expression profiles and
summarize differences in profiles between groups by using a test statistics based on
functional principal component scores that enables differential expression testing. This
idea enables finding differences in shape change by representing the expression profile of
a gene by a functional curve, called a gene expression function, and this approach is
especially powerful in detecting alternative splicing 22. Although functional data analysis
techniques appear to offer many advantages to genomic studies, such methods have not
been explored for analyzing DNA methylation data. FPCA has a natural application to aid
in solving the issue of testing for differentially methylated regions (DMRs), but the data
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collected and defining of regions differs from that of gene expression data and thus the
following formulation is needed in the DNA methylation context.
In this study, the methylation profile across CpG sites is decomposed within a
predefined region by using functional principal components and calculating the FPC scores
to test for DMRs between two groups (e.g., cases and control) of samples. The FPCA scores
related to an eigenfunction are computed for all observed methylation profiles in each
genomic region and can indicate eigenfunctions with large variation between two groups.
The methylation profile function is defined as follows. Let 𝑡 be the genomic position of
CpG site within a predefined genomic region and 𝑇 be the length of the genomic region
being considered. Assume that random samples from two different conditions are collected
and sequenced via RBBS. There are 𝑛𝐴 case samples and 𝑛𝐵 controls samples. Let 𝑥𝑖 (𝑡)
denote the methylation level for the CpG site at genomic position 𝑡 for the 𝑖th case sample
with 𝑦𝑖 (𝑡) defined similarly for the 𝑖th control sample. Thus 𝑥𝑖 (𝑡) and 𝑦𝑖 (𝑡) are empirical
methylation functions 22.
First, as a brief review of functional principal component analysis (FPCA)
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,

consider the following. Let 𝑋(𝑡) be a centered, square-integrable function, describing the
methylation level of CpG sites over the predefined region. Let 𝜙1 ,𝜙2 , … be the
orthonormal eigenfunctions of the covariance function of 𝑋 (𝑡). By the Karhunen Loève
theorem
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, the centered process in the eigenbasis functions can be expressed as 𝑋(𝑡) =

∑∞
𝑘=1 𝜉𝑘 𝜙𝑘 (𝑡), where 𝜉𝑘 = ∫ 𝑋(𝑡) 𝜙𝑘 (𝑡) 𝑑𝑡 is the principal component coefficient
associated with the 𝑘th eigenfunction 𝜙𝑘 (𝑡), with 𝐸(𝜉𝑘 ) = 0, 𝑉𝑎𝑟(𝜉𝑘 ) = 𝜆𝑘 , and
𝐸(𝜉𝑘 𝜉𝑙 ) = 0 for 𝑘 ≠ 𝑙. The covariance function 𝑅(𝑠, 𝑡) can be written as 𝑅(𝑠, 𝑡) =
22
𝐶𝑜𝑣(𝑋(𝑠), 𝑋(𝑡)) = ∑∞
𝑘=1 𝜆𝑘 𝜙𝑘 (𝑠) 𝜙𝑘 (𝑡) .
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The first eigenfunction 𝜙1 represents the principal mode of variation in 𝑋(𝑡) in that
𝜙1 (𝑡)

maximizes

the

variance

of

𝜉 = ∫ 𝑋(𝑡) 𝜙(𝑡) 𝑑𝑡 where

𝑉𝑎𝑟[∫ 𝑋(𝑡) 𝜙(𝑡) 𝑑𝑡 ] = ∫ ∫ 𝜙(𝑠) 𝑅(𝑠, 𝑡) 𝜙(𝑡) 𝑑𝑠𝑑𝑡 22.

This

𝜙1 (𝑡)

𝑉𝑎𝑟(𝜉) =

represents

the

dominant mode of variation in methylation levels over the region. Similarly, 𝜙𝑘 is the
function that maximizes 𝑉𝑎𝑟(𝜉) in the functional space that is orthogonal to 𝜙1 , … , 𝜙𝑘−1 .
Using the above information, the eigenfunctions { 𝜙1 , 𝜙2 , …} should satisfy
∫ 𝑅(𝑠, 𝑡)𝜙𝑘 (𝑠)𝑑𝑠 = 𝜆𝑘 𝜙𝑘 (𝑡),

(1)

where 𝜆1 ≥ 𝜆2 ≥ 𝜆3 ≥ ⋯ for any integer 𝑘 ≥ 1. The eigenfunctions { 𝜙1 ,𝜙2 , ..} can be
found by solving equation (1) 22.

2.1. PERFORMING FPCA ON DNA METHYLATION DATA
In the context of this study, FPCA can be performed to find the eigenfunctions and
corresponding principal components as follows 22. Let 𝑋(𝑡) = [𝑋1 (𝑡), 𝑋2 (𝑡), … 𝑋𝑁 (𝑡)]𝑇 be
a vector-valued function, with 𝑋𝑖 (𝑡) denoting the methylation profile function for the 𝑖𝑡ℎ
sample among 𝑁 replicates in the predefined region. A set of orthonormal basis functions
are selected using either a Fourier or B-spline basis. Note that the Fourier basis is typically
used for periodic data, while B-spline basis is used for non-periodic data. Both will be
explored since it is unclear which will work best for methylation data. The chosen basis
has 𝑃 functions ∆(𝑡) = [𝛿1 (𝑡), 𝛿2 (𝑡), . . , 𝛿𝑃 (𝑡)], where it is assumed that the methylation
functions 𝑋1 (𝑡), … , 𝑋𝑁 (𝑡) in the predefined region and eigenfunctions {𝜙1 ,𝜙2 ,..} can be
expressed as a linear combination of 𝛿1 (𝑡), 𝛿2 (𝑡), … , 𝛿𝑃 (𝑡). Now the methylation profile
function can be expressed as, 𝑋(𝑡) = 𝐶∆(𝑡), where the 𝑖𝑗th element in the matrix 𝐶 is
𝐶𝑖𝑗 = ∫ 𝑋𝑖 (𝑡) 𝛿𝑗 (𝑡)𝑑𝑡, with 𝑖 = 1, … , 𝑁 and 𝑗 = 1, … , 𝑃. Similarly, 𝜙(𝑡) can be expressed

29
as 𝜙(𝑡) = Δ𝑇 (𝑡)𝛽, where 𝛽 = [𝛽1 , … , 𝛽𝑃 ]𝑇 with 𝛽𝑗 = ∫ 𝜙(𝑡)𝛿𝑗 (𝑡)𝑑𝑡. To find the
eigenfunctions 𝜙, or equivalently, to determine 𝛽, use Equation (1), which has the
following equivalent expression 22:
𝜉1
.

𝛽1
.

𝛽1
.

𝑃

𝑃

𝑃

𝐸 [(𝜉. ) (𝜉1 … 𝜉𝑃 )] (𝛽. ) = 𝜆 (𝛽. )

(2)

Replace 𝐸(𝜉𝑖 𝜉𝑗 ) with its empirical estimate from sample methylation region functions
𝑋1 (𝑡), … , 𝑋𝑁 (𝑡) to obtain an empirical version of Equation (2):
1
𝑁

𝐶 𝑇 𝐶𝛽 = 𝜆𝛽.

(3)

The eigenfunctions can be found by solving for the above multivariate eigenvalue (𝜆) and
multivariate eigenvector (𝛽). The number of eigenfunctions can be chosen based on the
percentage of variance explained. In this study, 90% was used, but this can be modified to
allow different function approximation accuracies 22.

2.2. TEST STATISTIC
The pooled empirical methylation profile 𝑥𝑖 (𝑡) of cases and 𝑦𝑖 (𝑡) of controls was
used to estimate the orthonormal principal component function 𝜙𝑗 (𝑡), 𝑗 = 1, … , 𝑘
(eigenfunctions), employing the basis expansion method 20. Let the corresponding principal
components associated with 𝜙𝑗 (𝑡) be 𝜉𝑖𝑗 and 𝜂𝑖𝑗 , for 𝑥𝑖 (𝑡) and 𝑦𝑖 (𝑡), respectively. The test
′
′
statistic was defined using 𝜉𝑖𝑗
𝑠 and 𝜂𝑖𝑗
𝑠 to evaluate the difference in average principal

component scores between the case and control samples. Vectors of averages of the
functional principal component scores in cases and controls are denoted by 𝜉 ̅ =
1
1
𝑛𝐴
𝑛𝐵
[𝜉1̅ , … , 𝜉𝑘̅ ]𝑇 and 𝜂̅ = [𝜂̅1 , … , 𝜂̅ 𝑘 ]𝑇 , where 𝜉𝑗̅ = 𝑛 ∑𝑖=1
𝜉𝑖𝑗 , and 𝜂̅𝑗 = 𝑛 ∑𝑖=1
𝜂𝑖𝑗 , 𝑗 =
𝐴

1, … , 𝑘. The pooled covariance matrix S is defined as follows:

𝐵
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𝑆=

1
𝑛𝐴 +𝑛𝐵 −2

𝑛𝐴
𝑛𝐵
(∑𝑖=1
(𝜉𝑖 − 𝜉 ̅)(𝜉𝑖 − 𝜉 ̅)𝑇 + ∑𝑖=1
(𝜂𝑖 − 𝜂̅ )(𝜂𝑖 − 𝜂̅ )𝑇 ), where 𝜉𝑖 = [𝜉𝑖1 , … , 𝜉𝑖𝑘 ]𝑇 ,
1

1

𝜂𝑖 = [𝜂𝑖1 , … , 𝜂𝑖𝑘 ]𝑇 . Let Λ = (𝑛 + 𝑛 ) 𝑆. Then, the test statistic is defined as 𝑇 2 = (𝜉 ̅ −
𝐴

𝐵

𝜂̅ )𝑇 Λ−1 (𝜉 ̅ − 𝜂̅ ). Note that this is a form of a Hotelling’s 𝑇 2 statistic. Under the null
hypothesis of no differential methylation between the case and control group in a specific
2
region, 𝑇 2 asymptotically follows a central 𝜒(𝑘)
distribution, where 𝑘 is the number of

functional principal components. To accurately estimate the 𝑝-value, it is best to use a large
number of replicates in each group 22. Note that since the number of regions is determined
prior to testing, the false discovery rate can be controlled across the entire set of region
level tests.

3. SIMULATION STUDY

3.1. DATA SOURCE
To evaluate the performance of the FPCA method a simulation study based on real
RRBS data was performed. Methylation data of bisulfite-sequenced DNA was obtained
from 4 patients with acute promyelocytic leukemia (APL) and 12 APL control samples.
This data set was obtained under accession number GSE42119 (National Center for
Biotechnology Information) 24. The RRBS data was preprocessed using Bismark version
0.5 (a reference genome alignment tool) that maps bisulfite treated sequencing reads to a
genome of interest and performs methylation calls in a single step 25.
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3.2. SIMULATION PLAN
To mimic methylation profile changes accurately, a simulation was constructed
from the RRBS data set described above following the same approach as in M3D 19. The
regions (CpG clusters) were defined as follows: (1) CpG sites that covered at least 75% of
samples were defined as frequently covered CpG sites and (2) a maximum distance of 100
base pairs to the nearest neighbor within a region was accepted. Using these criteria, only
regions with at least 20 frequently covered CpG sites were used in the analysis
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. The

simulation study focused on the first 1,000 regions on chromosome 1. Out of the 12 APL
control samples in the RRBS data, 4 patients were randomly selected to use in the
simulation study as controls. Four more replicates were simulated 100 times to be the
testing group (i.e., cases). Of these, 250 of the CpG clusters (predefined regions) were
randomly selected to apply differential methylation changes. The replicates that acted as
the testing group (cases) were simulated by first adding or subtracting random Poisson (𝜆 =
1) noise to the total number of reads at each cytosine. Uniform [−0.1 to 0.1] random noise
was added to cytosine methylation levels. The methylation level 𝐿𝑖 , defined as the ratio of
methylated reads to total reads mapped to a particular cytosine, was adjusted within the
250 selected, predefined regions 19. The degree of methylation level change was controlled
by the parameter 𝛼 ∈ [0,1]; new methylation levels were simulated by 𝐿𝑛𝑒𝑤
=
𝑖
(1 − 𝛼)𝐿𝑜𝑙𝑑
+ 𝛼 when 𝐿𝑜𝑙𝑑
≤ 0.5 for hypermethylation (methylation higher in case than
𝑖
𝑖
control) and 𝐿𝑛𝑒𝑤
= (1 − 𝛼)𝐿𝑜𝑙𝑑
when 𝐿𝑜𝑙𝑑
> 0.5 for hypomethylation (methylation
𝑖
𝑖
𝑖
lower in case than control) 19.
FPCA and M3D were applied to all 100 simulated data sets under various settings.
For FPCA, both Fourier and B-spline basis were investigated. In general, 15-37 knots, with
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polynomial order 4, seemed to be a reasonable model for the FPCA-B-spline. To
investigate the performance of the methods under different degrees of differential
methylation the alpha parameter was varied as 𝛼 = {0.4,0.6,0.8,1}. To examine the
robustness of the methods for various experimental design features, two different
sequencing depths (5 and 20 reads) were simulated and three different replicate numbers
per group (3, 8, 12) were simulated. Methods were compared by calculating the average
type I and type II error rates across 100 data sets as well as the true positive rate (TPR).
The false discovery rate (FDR) was controlled at 0.05 for all analyses 26.

4. RESULTS

4.1. SIMULATION RESULTS
The results using FPCA were compared with the results using M3D. Table 2.1
summarizes the results obtained for different values of the methylation change strength
parameter 𝛼 and different basis expansions, based on an average sequencing depth of 20
reads. The average and standard deviation for the correct number of DMRs is given along
with type I and type II errors for each method. Of the 250 truly differentially methylated
regions (DMRs), FPCA under the Fourier expansion approach identified 229.85 on
average, with 3.93 falsely called DMRs when 𝛼 =100%. The FPCA under the B-spline
expansion approach identified 229.03 true DMRs on average, with 4.08 falsely called
DMRs and M3D identified 224.51 true DMRs on average, with no falsely called DMRs at
𝛼 = 100%.
FPCA–Fourier correctly identified 229.02 DMRs on average, while FPCA-Bspline
correctly identified 227.03 at a methylation level difference of 80%, with 3.07 and 3.41
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falsely called DMRs on average respectively. M3D called 222.94 true DMRs on average,
with no falsely called DMRs. At 𝛼 = 60%, the FPCA-Fourier and FPCA-B-spline correctly
identified 219.82 and 219.05 DMRs on average, respectively, with 2.97 and 3.03 falsely
called DMRs on average; whereas M3D called 202.95 correct DMRs on average,with no
falsely called DMRs. At 𝛼 = 40% the FPCA-Fourier and FPCA-Bspline correctly identified
212.5 and 207.88 DMRs on average, respectively, with 2.47 and 2.46 falsely called DMRs
on average; whereas M3D correctly called 190.07 DMRs on average, with no falsely called
DMRs.

Table 2.1. Results for Average and Standard Deviation (S.D.) of 100 Simulations Based
on FPCA-Fourier, FPCA-BSpline and M3D on Average Sequencing Depth (20 Reads),
with Various Levels of Strength of Methylation Change (α)
100%

Alpha

80%

Methods

FPCAFourier

FPCABspline

M3D

Correct

229.85

229.03

S.D.

0.796

FPCABspline

M3D

224.51 229.02

227.03

0.784

0.502

0.840

4.08

0

0.794

0.977

# Type-2 20.15

0.796

# Type-1 3.93

S.D.

S.D.

FPCAFourier

60%
FPCAFourier

40%

FPCABspline

M3D

222.94 219.82

219.05

0.809

0.502

0.783

3.07

3.41

0

0

0.877

1.090

20.97

25.49

20.98

0.780

0.502

0.840

FPCAFourier

FPCABspline

M3D

202.95 212.5

207.88

190.07

0.845

0.757

0.833

0.794

0.781

2.97

3.03

0

2.47

2.46

0

0

0.892

0.934

0

0.501

0.900

0

22.97

27.06

30.18

30.95

47.05

37.5

42.12

59.93

0.809

0502

0.783

0.845

0.757

0.833

0.794

0.781

In conclusion, all methods had a low average type I error rate with the maximum
being 0.0054 in FPCA-Bspline when 𝛼 = 100%. It should be noted that M3D did not
produce any type I errors, making it the most conservative of the methods but at the
sacrifice of higher type II errors (i.e., lower power). M3D had higher type II errors across
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all values of 𝛼 than both FPCA methods. Results were similar for FPCA-Fourier and
FPCA-Bspline, with FPCA-Fourier having slightly lower type II errors and thus giving it
a slight advantage. Across all methods, there were fewer type II errors as 𝛼 increased from
40% to 100%, which is expected since it is easier to detect more extreme differences.
However, it is notable that for small 𝛼 values, 𝛼 = 0.40, 0.60, there are more extreme
differences between M3D and the FPCA methods. This indicates FPCA can improve DMR
detection in more difficult situations when “the signal” is low.
In contrast, Table 2.2 displays the results based on an average sequencing depth of
5 reads. At methylation strength 100%, FPCA-Fourier and FPCA-B-spline called 223.88
and 222.5 DMRs on average, respectively, out of the 250 true DMRs, with 5.97 and 6.2
false DMRs. M3D called only 200.04 true DMRs on average, with no false DMRs. The
number of truly identified DMRs decreased using FPCA-Fourier, FPCA-Bspline and M3D,
when decreasing the strength of methylation change from 𝛼 = 80% to 40%, as was also
observed in Table 2.2.

Table 2.2 Results for Average and Standard Deviation (S.D.) of 100 Simulations Based on
FPCA-Fourier, FPCA-B-Spline, and M3D on Average Sequencing Depth (5 Reads), with
Various Levels of Strength of Methylation Change (α)
100%

Alpha

80%

Methods

FPCAFourier

FPCABspline

M3D

#
Correct

223.88

222.5

S.D.

0.819

# Type-1 5.97
S.D.

1.041

# Type-2 26.12
S.D.

0.819

FPCAFourier

60%

FPCABspline

M3D

200.04 219.15

219.08

0.885

0.815

0.832

6.2

0

1.470

FPCAFourier

40%

FPCABspline

M3D

197.13 202.06

211.09

0.812

0.824

0.826

6.05

6.15

0

0

1.426

1.431

27.5

49.96

30.85

0.885

0.8155 0.821

FPCAFourier

FPCABspline

M3D

178.00 197.93

200.02

170.05

0.829

0.804

0.843

0.791

0.808

3.94

3.71

0

4.54

5.07

0

0

0.887

1.112

0

0.8946

1.029

0

30.92

52.87

47.94

38.91

72.00

52.07

49.98

79.95

0.812

0.824

0.826

0.829

0.804

0.843

0.791

0.808
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Overall, similar trends were observed at 5 reads as for 20 reads, except that FPCABspline had slightly lower type II errors than FPCA-Fourier at 𝛼 = 0.4, 0.60 when the
sequencing depth was 5 reads (this was reversed for 20 reads). Also, all the methods had
higher type II errors at 5 reads than 20 reads while still maintaining a low type I error rate
on average. It should be noted that when the sequence depth is 5 reads there are more
drastic differences between the FPCA and M3D methods even for the largest 𝛼 = 100%
(i.e., across all 𝛼).

Figure 2.1. True Positive Rates Based on the Average over 100 Simulations on Average
Sequencing Depths of 5 (left graph) and 20 (right graph) Reads verses α Level for
Controlling the Degree of Differential Methylation for Each of Three Methods: FPCA
(Fourier Expansion Approach) – Blue, FPCA (B-Spline Expansion Approach) – Red, M3D
– Green.

Figure 2.1 shows the average true positive rates (TPRs) over the 100 simulated
data sets for varying degrees of differential methylation (𝛼 values) for each of the three
methods (FPCA-Fourier, FPCA-Bspline, and M3D) and two coverage depth (5 and 20
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reads). The FPCA-Fourier method had the highest average TPR with an average
sequencing depth of 20 reads across all 𝛼 values, with FPCA-Bspline yielding similar but
slightly lower TPRs. However, in an average sequencing depth of 5 reads, FPCA-Fourier
had the highest average TPR only when 𝛼 = 80%, 100%. For the lower levels of differential
methylation strength 𝛼 = 0.4, 0.60, the FPCA-B-spline had the highest TPR. Overall,
FPCA-Fourier and FPCA-B-spline substantially outperformed M3D with regard to TPR in
both average sequencing depths (5 and 20 reads), across all levels of differential
methylation strength. The coverage is also important to investigate, since low coverage can
lead to less stable methylation estimates and prevent statistical significance while high
coverage costs more to obtain. Figure 2.1 shows that the sequencing depth of 20 has the
highest average TPR compared to average sequencing depth of 5. However, this difference
is more drastic for M3D than it is for the FPCA methods. The FPCA methods maintain an
average TPR between 79% and 90% for a depth of 5 reads; whereas the M3D TPR ranges
from 68% to 80%.

4.2. ROBUSTNESS IN REPLICATIONS
To examine the robustness of the FPCA method to changes in replication number,
simulated data sets were created for differing numbers of replicates per group, using the
same approach as described as in section 3.2. Control samples from real RRBS data set
were used as the control groups for 3, 8 and 12 replicates per group. This was possible
since the data set contained 12 control samples. A set of 3, 8, or 12 replicates were
simulated as previously described to act as the cases groups. As before, the same 250
regions were simulated to be true DMRs using 𝛼 = 80% and a coverage of 20 reads. The
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FPCA-Fourier basis function method was used to identify DMRs with 3, 8 and 12 replicates
per group since this method performed best for 20 reads and these results were compared.
The false discovery rate (FDR) was controlled at 5%. The FPCA-Fourier method identified
179, 193, and 216 true DMRs out of the total of 250, with 3, 8, and 12 replicates per group,
respectively.

Figure 2.2. Venn Diagram of True DMRs Detected with FPCA-Fourier, for 3, 8, and 12
Replicates Per Group. The Number and Percentage of Type I and Type II Errors is also
Given for Each Replicate Number.

As shown in Figure 2.2, the overlap between the three sets of true DMRs identified
accounts for 70% of the total. As was expected, the testing lost power with lower
replication, with 12 replicates per group identifying the most unique true DMRs and having
the lowest number of type II errors, and the highest number of type II errors occurred for
three replicates per group. More similarity was observed between the simulations with
eight and 12 replicates as they shared 15 true DMRs uniquely, whereas the simulation with
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three replicates had no unique overlap with eight or 12 replicates. Overall, the type II error
rates ranged from 13.6% in the 12 replicate cases to 28.4% in the three replicate cases.
Type I error was low for all three cases with the lowest being 0.13% for 12 replicates and
the highest being 0.53% for three replicates. This shows that while more replicates are
better, the FPCA- Fourier method exhibits a reasonable amount of robustness to smaller
replicate number per group.

4.3. DMRS DETECTED IN REAL DATA
An analysis was completed using the real RRBS data described in section 3.1 with
four samples from bone marrow patients with acute promyelocytic leukemia (APL) and
four control samples (APL in remission). All CpG sites (with at least 20 reads) across all
samples were used, including all regions with start and stop locations defined as described
in section 3.2. Since this data set provided a coverage of at least 20 reads, the FPCA-Fourier
method was applied since it performed the best under that setting and these results were
compared to M3D.
Out of 14,000 CpG regions selected for testing, FPCA-Fourier identified 3897 DMRs
and M3D identified 2603 DMRs total, with 1488 DMRs in common. Figure 2.3 confirms
that the FPCA-Fourier method identified a clear group of changed profiles between the two
conditions in the real data sets. The false discovery rate (FDR) was controlled at 0.05 for
all analyses 26.
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Figure 2.3. Venn Diagram Comparing the Number of Significant Differentially Methylated
Regions (DMRs) Identified by the FPCA-Fourier and M3D Methods in the Real APL
RRBS Data Set.

5. CONCLUSION
This research demonstrates that information from reduced representation bisulfite
sequencing (RRBS) datasets can be analyzed using higher-order mathematics, specifically
a functional data analysis approach. Here, a dimension reduction approach is presented,
based on the Karhunen-Loève transform, to create a hypothesis test for differential
methylated regions (DMRs) using functional principal components based on the spatial
features of methylation profiles. This allows the investigation of dominant modes of
variation in the methylation profile over a region using eigenfunctions of the covariance
function. The FPCA in this study employs a few principal components that increase the
power and reduce degrees of freedom in testing to make the underlying biological signals
stable. An FPCA based on Fourier and B-spline functions was developed that successfully
detects information from shapes of the methylation curves that cannot be identified by
traditional multivariate statistics and tests for differentially methylated regions between
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case and control groups. An empirical comparison, using a simulation based on real data,
showed a substantial increase in the true positive rate for FPCA in comparison with the
M3D approach 19, as well as considerable robustness with respect to coverage depth and
replication. In general, the simulation results were similar for FPCA-Fourier and FPCABspline, with FPCA- Fourier having slightly lower type II errors across most of the
simulation settings thus giving it a slight advantage.
The good performance of the FPCA method is attributable to a number of factors.
First, the method takes spatial correlation into account in analyzing the methylation profile.
Second, the FPCA translates high-dimensional DNA methylation data into a few principal
components, which greatly reduces the degrees of freedom in testing, while preserving
most of the underlying biological signals. In contrast M3D, does not perform well in high
dimensional DNA methylation data within a region.
The methodology proposed and illustrated here builds on the interpretation of nextgeneration sequencing data. The FPCA method can be applied in cancer research as well
as in the pursuit of therapies to combat or prevent lupus, muscular dystrophy, and other
diseases. In fact, because hypermethylation occurs early in colon cancer, detection of
hypermethylation could be an important indicator of potential health problems, which
might be detected using the FPCA method. In addition, future studies are needed to
investigate the use of other functional data analysis techniques, such as functional linear
regression or functional canonical correlation analysis, as well as incorporating smoothing
penalties into the analysis. Although the FPCA framework was investigated using RRBS
data, it should scale up well for utilization in whole genome bisulfite sequencing studies,
but this should be investigated more fully. Finally, although the FPCA method exhibited
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robustness in detecting DMRs under 1ow coverage and replications in two groups, it is of
interest to extend the method to work for experiments that require testing for differences
between more than two groups or that have covariate information.
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ABSTRACT
DNA methylation is a key, heritable, epigenetic modification that can alter gene
expression without a DNA sequence change. Most instances of DNA methylation in
mammals take place when a methyl group attaches to a cytosine when followed by a
guanine (CpG dinucleotides) on the DNA sequence. DNA methylation can be measured
throughout the genome at individual cytosine sites by combining bisulfite sequencing with
next-generation sequencing (NGS). Although the measurements are taken at the site level,
researchers are often interested in testing for methylation differences over genomic
regions. Although DNA methylation has been well researched, little statistical research has
been conducted to develop methods that will discover epigenomic structural variations
using NGS data to identify predefined differentially methylated regions (DMRs). This
study addresses this critical gap in the literature, by creating a new strategy that evaluates
predefined methylation regions (DMRs) using smoothed functional principal component
analysis (SFPCA). This study compares the performance of SFPCA to FPCA without
smoothing and to an existing method, M3D, using real and simulated data.
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1. INTRODUCTION
DNA methylation has been researched in depth because it is an important, heritable,
epigenetic modification that can alter gene expression without changing the DNA
sequence. In mammals, DNA methylation is almost always the result of a methyl (CH3)
group attaching to a cytosine when followed by a guanine (CpG dinucleotides) on the DNA
sequence. Methylation can modify the way genes function after a methyl group has been
added to the DNA. DNA methylation is one of the best characterized epigenetic
modifications and its connection to human health has been heavily studied but is not yet
fully understood 1. In mammals, it is involved in various biological processes including the
silencing of transposable elements, regulation of gene expression, genomic imprinting, and
X-chromosome inactivation 1. The methylation of CpG locations in promoter regions is
often associated with gene silencing; however, recent research suggests that the correlation
between CpG methylation with gene bodies and gene expression is more complex 2.
The most thorough method for measuring DNA methylation is bisulfite sequencing
combined with next-generation sequencing (NGS), which has the advantage of quantifying
single-base cytosine methylation levels across the entire genome 25. In bisulfite sequencing,
DNA is treated with sodium bisulfite, which converts unmethylated cytosine residues to
uracil, but which does not affect the 5` methylcytosine residues. After PCR amplification,
the uracils are converted to thymines, thus enabling a distinguishing between methylated
and unmethylated cytosines. Bisulfite converted DNA fragments are then sequenced via
NGS and aligned to a reference genome. The percentage of methylation at each cytosine
position is found by calculating the ratio (C/C+T), that is the number of methylated reads
(C) divided by the total of all methylated and unmethylated reads (C+T). Several
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techniques can be used for high-throughput bisulfite sequencing, including reduced
bisulfite sequencing (RRBS) 3, whole-genome shotgun bisulfite sequencing methods (BSseq, methylC-seq) 4, 5, and target capture bisulfite sequencing7. Although the whole genome
methods such as BS-seq and MethylC-seq provide the most complete information, cost is
still a limitation for many studies. Alternatively, RRBS allows for the use of restriction
enzymes, such as MspI or TaqI, to cleave at CCGG loci so as to choose an informative set
of short reads to sequence 8. This process provides more accurate and specific results within
specific subsets of the genome, with greater coverage of CpG-dense regions, and is less
expensive than sequencing all cytosines genome wide.
A major problem in computational epigenomics is that epigenetic signals are poorly
understood. However, new statistical methods and software tools that identify differentially
methylated sites and regions (DMRs)

8-10

have been developed recently to aid in

understanding these complex data. Although many initial methods focused on testing
individual cytosine sites, there are biological and statistical benefits of testing regions
instead of sites. While the site level data may be noisy, the overall regions tend to be more
informative and there are fewer of them to test, easing the burden of the multiple testing
problem. Additional advantages of using DMRs are that although differences at any given
site may be small, variations across a region can be detected more easily due to the high
correlation neighboring sites

11

and DMRs potentially have a greater ability to predict

phenotypes.
Region level testing methods can be categorized into those that operate on
predefined regions verses those that define the region after site level testing has taken place,
and thus cannot be defined in advance. Both methods need to control the false discovery
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rate (FDR) at the region-level, but when the number of regions is not determined prior to
testing this task is non-trivial, making it more difficult to control for multiple test for such
methods. For example, when the regions are undefined before testing, it is impossible to
extrapolate the region-level FDR control from the site-level tests in the region. As such,
the best approach is to use predefined regions, defined based on annotation regions (e.g.,
CpG islands, CpG shores, introns, and exons), or defined based on a non-annotation criteria
(Figure 3.1) 12. Often, non-annotation regions are defined based on locating regions with a
certain minimum CpG density within a specific genomic window.

Figure 3.1. Illustration of Predefined Regions Based on Annotation and Non-Annotation
Profiles. Image modified from Baumann and Doerge 12.

Both types of predefined regions have pros and cons. Annotation based regions may
have a direct biological meaning but if the CpG sites are sparse or separated by more than
1000 bp, the known correlation in methylation levels between neighboring sites may be
diminished for different parts of the region. When regions are defined based on CpG
density within a certain neighborhood this problem is alleviated, at the sacrifice of
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potentially less biologically meaningful regions. This can be somewhat overcome by
determining which annotation units overlaps with the defined region.
Many approaches can be employed to define DMRs. Many region-level methods
first test each cytosine site to search for DMRs, then follow the site level results with posthoc aggregation. These are the methods mentioned previously where the regions being
tested are not known in advance, and a method is needed to control the type I error rate
while also letting the data determine where to look. BSmooth 8, which is a widely cited
method, employs a smoothing process of methylation levels across the genome for each
sample, which improves the accuracy of the methylation level estimate for any single CpG
site. To discover DMRs, BSmooth combines individual cytosines with ranked (significant)
differentially methylated cytosines (DMCs), which are found using t-statistics or a linear
model, with a quantile or direct t-statistic cutoff 8. Most of the newer approaches (e.g.,
BiSeq 13 and methylSig14) use local smoothing, with a beta binomial model of methylation
levels at individual cytosine sites. Both BiSeq and methylSig aggregate the results of tests
at discrete loci when computing a measure of significance for estimating DMRs.
Among methods that use predefined regions, MethylKit uses annotation to provide
a statistical test that pools the sequencing reads across an annotated unit (e.g., gene) by
group. When using multiple samples, a logistic regression with a binary predictor
corresponding to the condition is applied, which can be expressed as a binomial-based test
10

. Thus methylKit still relies on post-hoc aggregation of site-level tests but the regions

where aggregation takes place are known in advance due to annotation information. In
contrast, the methylation analysis using genome information (MAGI) tests directly for
DMRs across annotation units rather than computing measures of significance for each
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region based on an examination of individual cytosine sites. This difference in methods
results from the assumption, under MAGI 12, that the regions are homogeneous in terms of
methylation and require no adjustments for spatial correlations between cytosine sites.
Methylation levels at each cytosine site are labeled with a binary representation showing
whether or not they exceed a specified decision boundary. A Fisher’s Exact Test (FET) for
unreplicated experiments or a logistic regression when replicates are available is performed
over each region, which counts the number of cytosine sites that have changed states 12.
An alternative method, M3D

15

, relies on the Maximum Mean Methylation

Discrepancy (MMD) method to assess changes in the shapes of methylation profiles within
the local predefined regions being tested. Regions are defined in M3D based on CpG
density rather than annotation. M3D applies a machine learning technique (MMD) 23 to test
the homogeneity in underlying methylation-generating distributions. The method uses a
radial basis function (RBF) kernel function to construct the MMD between data sets in
each region being tested and this number is modified based on changes in coverage profiles.
The M3D statistics are compared to a null distribution of observed M3D statistics between
replicate pairs 15. It has been suggested that the shape of the methylation profile is a crucial
factor in predicting gene expression, supporting the notion of a functional role for the
methylation pattern

23

. This is one of the advantages of M3D’s idea of looking at the

differences in shape change over a predefined region in methylation profile. In a review
of the literature, it appears that only the M3D method utilizes the shape of the methylation
profile over the region (Figure 3.2).
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Figure 3.2. Methylation Profiles of Predefined Regions Identified by the M3D Method in
a Comparison of Leukemia and Human Embryonic Stem Cells (ESC). Figure from Mayo
et al. 15.

Although M3D offers certain advantages, there may be more information that can
be captured about the shape of the methylation profile over a region than is used in M3D.
In the previous paper (Section 2), a functional principal component analysis (FPCA)
approach was proposed to capture dominant modes of variation in the methylation level
across a region. FPCA was shown to greatly improve power to identify DMRs over M3D,
indicating the benefit of considering additional aspects of the curve shape beyond those
used in M3D. However, the observed methylation profiles are typically not smooth, which
lead to substantial variability in the estimated functional principal component curves.
When the epigenetic methylation function changes rapidly within the genomic region, the
basis expansion in the FPCA may not provide a good estimate of the genetic variation, thus
potentially decreasing the power of FPCA. In this study, this limitation was overcome by
developing a smoothed FPCA (SFPCA) for testing DMRs by combining a goodness-of-fit
measure with a roughness penalty on the functional principal component weight functions
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to maintain the advantages of basis expansion. SFPCA explicitly accounts for adjusting
spatial correlations between cytosine sites. Rather than only testing at individual cytosine
sites, this method can find changes in methylation profiles across predefined regions based
on CpG density. This study compares the performance of SFPCA to FPCA without
smoothing and to the existing method (M3D) for shape changes in predefined regions,
using real and simulated data.

2. METHODS

2.1 SMOOTHED FUNCTIONAL PRINCIPAL COMPONENT ANALYSIS
In this section, a smoothed functional principal component analysis (SFPCA) is
developed for testing for region-level differential methylation. SFPCA has been shown to
be beneficial in other areas of genomics, specifically in association studies where it can be
used for testing across the entire allelic spectrum (rare and common) of genetic variation
18

. One goal of this paper was to employ SFPCA for a group test across a genomic region.

In this approach, smoothed functional principal component scores take information across
all variants in the genomic region into account, hence including all single variant variation
while constructing a region level test

18

. This SFPCA method could be highly beneficial

for DNA methylation data, yet no functional data analysis techniques have currently been
developed for region level differential methylation detection. Here, an SFPCA method is
developed for summarizing the methylation profile in region.
DNA methylation levels are often strongly spatially correlated between
neighboring CpG sites

28

. The SFPCA developed below serves as dimension reduction

approach of the finite methylation profile using the Karhunen-Lo𝑒́ ve transform to show the
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variability existing between RRBS datasets under differing conditions with respect to a
defined region of interest 18. This allows the investigation of dominant modes of variation
in the data using the eigenfunctions of the methylation profile covariance function. Let 𝑡
be a genomic position of a cytosine site within a genomic region, and let 𝑇 be the length of
the genomic region under consideration. If the CpG density of the genomic region is high,
the region [0, T] can be rescaled to [0, 1]18, where 𝑡 is a continuous variable over the
interval [0,1]. Assume that RRBS data are collected on samples in two conditions (e.g.,
cases and control) with 𝑛𝐴 case samples and 𝑛𝐵 control samples.
Let 𝑋(𝑡) be the centered, epigenetic methylation function to describe each region.
In this study, the epigenetic methylation function represents methylation levels of CpG
sites described over a predefined region. When using functional principal component
analysis (FPCA) 16, the variation in the epigenetic methylation function can be expressed
with a linear combination of the functional values:
1

𝑓 = ∫0 𝜉(𝑡)𝑋(𝑡)𝑑𝑡

(1)

where 𝜉(𝑡) is a weight function. The functional principal components can be found by
finding the weight function 𝜉(𝑡) that maximizes the variance of 𝑓 16:
1

1

𝑣𝑎𝑟(𝑓) = ∫0 ∫0 𝜉(𝑠)𝑅(𝑠, 𝑡) 𝜉(𝑡)𝑑𝑠𝑑𝑡

(2)

where 𝑅(𝑠, 𝑡) describes the covariance function of each epigenetic methylation function
for each predefined region. The methylation profiles are not normally smooth, which
causes there to be considerable variability when estimating the functional principal
component curves. A roughness penalty is used in combination with the functional
principal component weight functions to aid with smoothness of the functional principal
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component 18. In this study, the roughness penalty on the functional principal component
weight functions utilizes the integrated, squared second derivative.
The smoothed functional principal components can be found by solving the
following integral equation 18:
1

∫0 𝑅(𝑠, 𝑡) 𝜉(𝑠)𝑑𝑠 = 𝜌[𝜉(𝑡) + 𝜆 ∥ 𝐷2 𝜉(𝑡) ∥2 ]

(3)

Where 𝜆 is a smoothing parameter that balances the function roughness and the fit. To
reduce the SFPCA to an unsmoothed FPCA, set 𝜆 = 0.

2.2. COMPUTATION FOR SFPCA
The principal component function is an eigenfunction that is an integral function
and is difficult to solve in closed form. To solve for the eigenfunction in Eq. (3), first
convert the continuous eigenanalysis to an appropriate discrete eigenanalysis 16. To obtain
this conversion, Fourier basis function methods can be used 18.
Let 𝛿𝑗 (𝑡) be a series of Fourier basis functions. For each 𝑗, define 𝜔2𝑗−1 = 𝜔2𝑗 =
2𝜋𝑗. Then, expand the epigenetic methylation function as a linear combination of the basis
function 𝛿𝑗 :
𝑋(𝑡) = ∑𝑇𝑗=1 𝐶𝑗 𝛿𝑗 (𝑡)

(4)

Let 𝑋(𝑡) = [𝑋1 (𝑡), … … … . , 𝑋𝑁 (𝑡)]𝑇 be a vector-valued function, with 𝑋𝑖 (𝑡) be a
centered, square-integrable function, in this case describing the methylation level of the 𝑡𝑡ℎ
CpG site in the predefined region for 𝑖𝑡ℎ sample for N replicates. Then, select an
orthonormal Fourier basis with 𝑇 functions 𝛿(𝑡) = [𝛿1 (𝑡), 𝛿2 (𝑡), … , 𝛿𝑇 (𝑡)]𝑇 . The joint
expansion of the N methylation profiles can then be expressed as follows 18:
𝑋(𝑡) = 𝐶𝛿(𝑡)

(5)
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where 𝐶 is a coefficient matrix and the covariance function of the methylation profiles can
be represented as
1

𝑅(𝑠, 𝑡) = 𝑁 𝛿 𝑇 (𝑠)𝐶 𝑇 𝐶𝛿(𝑡).

(6)

Also, the eigenfunction can be written as
𝝃(𝒕) = ∑𝑻𝒋=𝟏 𝒃𝒋 𝜹𝒋 (𝒕) and 𝑫𝟒 𝝃(𝒕) = ∑𝑻𝒋=𝟏 𝝎𝟒𝒋 𝒃𝒋 𝜹𝒋 (𝒕) or
𝝃(𝒕) = 𝜹(𝒕)𝑻 𝒃 and 𝑫𝟒 𝝃(𝒕) = 𝜹(𝒕)𝑻 𝒗𝟎 𝒃

(7)

where 𝒃 = [𝒃𝟏 , … . , 𝒃𝑻 ]𝑻 and 𝒗𝟎 = 𝒅𝒊𝒂𝒈(𝝎𝟒𝟏 , … . , 𝝎𝟒𝑻 ).
The right term can be expanded in Eq. 3 as
𝝃(𝒕) + 𝝀 ∥ 𝑫𝟐 𝝃(𝒕) ∥𝟐 = 𝜹(𝒕)𝑻 𝒗−𝟐 𝒃.
𝟏

(8)

𝟏

where 𝒗 = 𝒅𝒊𝒂𝒈((𝟏 + 𝝀𝝎𝟒𝟏 )−𝟐 , … . , (𝟏 + 𝝀𝝎𝟒𝑻 )−𝟐 ).
Substituting Equations 6 and 7 for 𝑹(𝒔, 𝒕) and 𝝃(𝒕) into the eigenequation (Eq. 3), results
in the following 18:
𝟏
𝑵

𝑪𝑻 𝑪 𝒃 = 𝝆 𝒗−𝟐 𝒃.

(9)

which can be written as
𝟏

𝟏

[𝒗 (𝑵 𝑪𝑻 𝑪) 𝒗] [𝒗−𝟏 𝒃] = 𝝆 [𝒗−𝟏 𝒃] , or 𝒗 (𝑵 𝑪𝑻 𝑪) 𝒗𝒖 = 𝝆𝒖

(10)

where 𝒖 = 𝒗−𝟏 𝒃. Therefore, 𝒃 = 𝒗𝒖 and 𝝃(𝒕) = 𝜹(𝒕)𝑻 𝒃 is a solution to eigenequation
(Eq. 3) 18.

2.3. TEST STATISTIC
To estimate the set of orthonormal principal component functions 𝜉𝑗 (𝑡), 𝑗 =
1,2, … 𝑘 (eigenfunctions), let the pooled methylation profiles 𝑥𝑖 (𝑡) denote the methylation
level for the CpG site at genomic position 𝑡 for 𝑖th case sample. Similarly define 𝑦𝑖 (𝑡) for
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the 𝑖th control samples. By the Karhunen-Lo𝑒́ ve decomposition 16, the smoothed functional
principal component score can be obtained by 𝛽𝑖𝑗 =< 𝑥𝑖 (𝑡), 𝜉𝑗 (𝑡) > and 𝜂𝑖𝑗 =<
𝑦𝑖 (𝑡), 𝜉𝑗 (𝑡) >, where 𝑗 = 1,2, … 𝑘. Let the average vectors of the functional principal
component scores in the cases and controls be 𝛽̅ = [𝛽1̅ , … . , 𝛽𝑘̅ ] and 𝜂̅ = [𝜂̅1 , … . , 𝜂̅𝑘 ]. The
pooled covariance matrix can be defined as 𝑆 = 𝑛

1

𝐴 +𝑛𝐵 −2

𝑛

𝐴
[(∑𝑖=1
(𝛽𝑖 − 𝛽̅ )(𝛽𝑖 − 𝛽̅ )𝑇 +

1

𝐵
∑𝑛𝑖=1
(𝜂𝑖 − 𝜂̅ )(𝜂𝑖 − 𝜂̅ )𝑇 )], where 𝛽𝑖 = [𝛽𝑖1 , … , 𝛽𝑖𝑘 ]𝑇 ,𝜂𝑖 = [𝜂𝑖1 , … , 𝜂𝑖𝑘 ]𝑇 . Let Λ = (𝑛 +
𝐴

1
𝑛𝐵

) 𝑆. Then, the Hotelling 𝑇 2 statistic test is defined as 𝑇 2 = (𝛽̅ − 𝜂̅ )𝑇 Λ−1 (𝛽̅ − 𝜂̅ ). Under

the null hypothesis of no differential methylation in the region between the case and control
2
group, 𝑇 2 asymptotically follows a central 𝜒(𝑘)
distribution, where 𝑘 equals the number of

functional principal components. For the most accurate estimate of the 𝑝-value, a large
number of replicates in each treatment group should be used

17

. The false discovery rate

can be controlled across all of these region level tests.

3. SIMULATION STUDY

3.1. DATA SET
To evaluate the performance of the SFPCA method, a simulation study based on
real RRBS data was performed. Methylation data of bisulfite-sequenced DNA was
obtained from 4 patients with acute promyelocytic leukemia (APL) and 12 APL control
samples 20. This data set was obtained under accession number GSE42119 (National Center
for Biotechnology Information)

21

. The RRBS data were preprocessed using Bismark

version 0.5; a reference genome alignment tool that maps bisulfite treated sequencing reads
to a genome of interest and performs methylation calls in a single step 25.
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3.2. SIMULATION PLAN
Using the simulation approach in M3D 1, and employing actual RRBS data, a
simulation was created to accurately imitate methylation profile changes. The regions
(CpG clusters) were defined as follows: (1) CpG sites that covered at least 75% of samples
were defined as frequently covered CpG sites and (2) a maximum distance of 100 base
pairs to the nearest neighbor within a region was accepted. Only regions with at least 20
frequently covered CpG sites were used in the analysis18. This investigation looked at the
first 1,000 regions on chromosome 1. Four biological replicates based on the controls in
the APL RRBS data set described above were randomly chosen out of the 12 as the control
group. Four replicates were simulated 100 times to be the case group. Differential
methylation changes for the case group were applied to 250 randomly chosen CpG clusters
(predefined regions). To create the case group, data for the replicates were simulated by
first adding or subtracting random Poisson (𝜆 = 1) noise to the total number of reads at
each cytosine. Uniform [-0.1 to 0.1] random noise was added to cytosine methylation
levels. The methylation level 𝐿𝑖 , which was defined as the ratio of methylated reads to the
total reads mapped to an individual cytosine site, was adjusted for all cytosine sites within
the 250 selected, predefined regions

15

. The parameter 𝛼 ∈ [0,1] was used to control the

degree of methylation level change. To simulate methylation level changes in the 250
regions, the following equations were used. If 𝐿𝑜𝑙𝑑
≤ 0.5 :
𝑖
then 𝐿𝑛𝑒𝑤
= (1 − 𝛼)𝐿𝑜𝑙𝑑
+ 𝛼 for hypermethylation (higher methylation in cases)
𝑖
𝑖

(11)

else 𝐿𝑛𝑒𝑤
= (1 − 𝛼)𝐿𝑜𝑙𝑑
𝑖
𝑖

(12)

for hypomethylation (lower methylation in cases).

The false discovery rate (FDR) was controlled at 0.05 for all analyses 21.
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To investigate the performance of SFPCA, a large scale simulation was performed
under various settings. The average type I and type II error rates as well as the average true
positive rate was calculated across the 100 simulated data sets. Performance of SFPCA was
compared to the existing method (M3D) for predefined regions, as well as to an FPCA
without the smoothing technique. The Fourier basis expansion was used for both FPCA
and SFPCA using 15-35 basis functions. Different degrees of differential methylation were
considered by varying the alpha parameter for 𝛼 = {0.4,0.6,0.8,1}. To examine the
robustness of the methods for various experimental design features, two different
sequencing depths (5 and 20 reads) were simulated and three replicate numbers per group
(3, 8, and 12) were simulated.

4. RESULTS

4.1. SIMULATION RESULTS
To assess the performance of SFPCA, results from the simulation study were
compared with results from M3D and Functional Principal Component Analysis (FPCA)
without smoothing. The average type I error, type II error and correct number of true DMRs
identified over 100 simulated data sets under varying differential methylation strength
parameters 𝛼 (based on an average sequencing depth of 20 reads) under the Fourier basis
expansion for both FPCA and SFPCA are illustrated in Table 3.1.
With a total of 250 true DMRs at 𝛼 = 100%, SFPCA found 239.87 true DMRs on
average, with 2.20 falsely called DMRs; FPCA found 229.85 true DMRs on average, with
3.93 false positives. Using M3D located 224.51 true DMRs on average, and found no false
positives. At a differential methylation strength of 80%, SFPCA correctly called 237.03 on
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average, with 2.11 false positives, while FPCA correctly called 229.02 on average, with
3.41 false positives. M3D correctly identified 222.94 DMRs on average, and found no false
positives. At a methylation strength of 60%, SFPCA correctly identified 226.97 DMRs on
average, with 2.48 false positives, whereas FPCA correctly identified 219.05 DMRs on
average, with 2.97 false positives on average. At methylation 60%, M3D correctly
identified 202.95 DMRs on average, and found no false positives. At a differential
methylation strength of 40%, SFPCA found 215.00 true DMRs on average, with 2.02 false
positives, while FPCA found 212.5 true DMRs on average, with 2.47 false positives. In
contrast, M3D correctly identified only 190.07 DMRs on average, but had no false
positives.

Table 3.1. Results for Average and Standard Deviation (S.D.) of 100 Simulations Based
on SFPCA, FPCA, and M3D on Average Sequencing Depth (20 Reads), with Various
Levels of Strength of Methylation Change (α)
100%

Alpha
Methods

SFPCA FPCA

# Correct 239.87

80%
M3D

SFPCA FPCA

60%
M3D

SFPCA FPCA

40%
M3D

SFPCA FPCA M3D

229.85 224.51 237.03

229.02 222.94 226.97

219.05 202.95 215.00

212.5

190.07

S.D.

0.774

0.796

0.502

0.797

0.809

0.502

0.822

0.783

0.757

0.804

0.833

0.781

# Type-1

2.20

3.93

0

2.11

3.41

0

2.48

2.97

0

2.02

2.47

0

S.D.

0.752

0.794

0

0.827

1.090

0

0.702

0.892

0

0.816

0.501

0

# Type-2

10.13

20.15

25.49

12.97

20.98

27.06

23.03

30.95

47.05

35.00

37.5

59.93

S.D.

0.774

0.794

0.502

0.797

0.804

0.502

0.822

0.783

0.757

0.804

0.833

0.781

Table 3.2 illustrates the sensitivity of the methods to fewer reads (average
sequencing of 5 reads) based on systematically altering the strength of the methylation
level difference 𝛼. The SFPCA method performed well for all of the 𝛼 values at an average

60
sequence depth of 5 and 20 reads compared to other methods. In summary, all methods had
low average type I error rate with the highest occurring in FPCA at a coverage of 5 reads
(Table 3.2) with average type I error rate of 0.008. M3D was the most conservative of the
methods as it did not produce any type I errors, but all methods controlled the type I error
rate well below 0.05. Across all settings, M3D had the highest type II error rate on average.
SFPCA and FPCA had similar type II error rates on average, but SFPCA had a slight
advantage as it always yielded lower type II errors across all settings.

Table 3.2. Results for Average and Standard Deviation (S.D.) of 100 Simulations Based
on SFPCA, FPCA, and M3D on Average Sequencing Depth (5 Reads), with Various
Levels of Strength of Methylation Change (α)
Alpha

100%

80%

60%

40%

Methods

SFPCA

FPCA

M3D

SFPCA

FPCA

M3D

SFPCA

FPCA

M3D

SFPCA

FPCA

M3D

# Correct

225.07

223.88

200.04

221.14

219.15

197.13

211.88

202.06

178.00

202.9

197.93

170.05

S.D.

0.831

0.819

0.815

0.791

0.832

0.824

0.782

0.826

0.804

0.834

0.843

0.808

# Type-1

4.95

5.97

0

4.95

6.05

0

3.56

3.94

0

4.99

4.54

0

S.D.

1.320

1.041

0

1.439

1.426

0

1.139

0.887

0

1.431

0.8946

0

# Type-2

24.93

26.12

49.96

28.86

30.85

52.87

38.12

47.94

72.00

47.1

52.07

79.95

S.D.

0.831

0.819

0.8155

0.791

0.821

0.824

0.782

0.826

0.804

0.834

0.843

0.808

Figure 3.3 shows the average true positive rates (TPRs) for varying degrees of
differential methylation (𝛼 values) for each of the three methods (SFPCA, FPCA, and
M3D) and two coverage depths (5 and 20). The SFPCA method had the highest average
TPR at an average sequencing depth of 5 and 20 reads across all levels of 𝛼. Overall,
SFPCA and FPCA substantially outperformed M3D with respect to TPR at both average
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sequencing depths (5 and 20 reads), and all levels of differential methylation strength.
SFPCA and FPCA performed similarly, with SFPCA always having a slight advantage that
is more magnified at larger alpha values in 20 reads. All methods have larger TPR for 20
reads compared to 5 reads. However, the TPR for SFPCA and FPCA are always above
80% under both coverage levels. It is also true that TPR increases as the strength of
methylation difference (𝛼) increases, but both SFPCA and FPCA consistently maintain
high average TPR greater than 80% indicating their ability to perform well even when the
“signal” is smaller.

Figure 3.3. True Positive Rates Based on the Average over 100 Simulations on Average
Sequencing Depths of 5 (left graph) and 20 (right graph) Reads verses α Level for
Controlling the Degree of Differential Methylation Region for Each of Three Methods:
Smoothed Functional Principal Component Analysis (SFPCA-Red), Functional Principal
Component Analysis (FPCA-Blue) and M3D-Green.

4.2. ROBUSTNESS IN REPLICATIONS
To examine the robustness of the SFPCA method to changes in replication number,
simulated data sets were created for differing numbers of replicates per group, using the
same approach as described as in section.3.2. Control samples from the real RRBS data set
were used as the control groups for 3, 8 and 12 replicates per group. This was possible
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since the data set contained 12 control samples. A set of 3, 8, or 12 replicates were
simulated as previously described to act as the cases groups. As before, the same 250
regions were simulated to be true DMRs using 𝛼 = 80% and coverage of 20 reads. The
SFPCA method was used to identify DMRs with 3, 8 and 12 replicates per group and these
results were compared. The false discovery rate (FDR) was controlled at 5%. The SFPCA
method identified 195, 195, and 228 true DMRs out of the total of 250, with 3, 8, and 12
replicates per group, respectively.

Figure 3.4. Venn Diagram of True DMRs Detected with SFPCA for 3, 8, and 12 Replicates
per Group.

As shown in Figure 3.4, the overlap between the three sets of true DMRs identified
accounts for 75% of the total. As was expected, the testing lost power with lower
replication, with 12 replicates per group identifying the most unique true DMRs and having
the lowest number type II error, and the highest number of type II errors occurred for 3 and
8 replicates per group. Overall the type II error rates ranged from 8.8% in the 12 replicate
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cases to 22% for 3 and 8 replicates per group. Type I error was low for all three cases with
the lowest being 0.13% for 12 replicates and the highest being 0.53% for 3 replicates. This
shows that while more replicates are better, the SFPCA method exhibits a reasonable
amount of robustness to smaller replicate numbers per group.

4.3. APPLICATION TO REAL DATA
An analysis was completed using the real RRBS data described in section 3.1 with
four samples from patients with acute promyelocytic leukemia (APL) and four control
samples (APL in remission). All CpG sites (with at least 20 reads) in both samples were
used, including all region start and stop locations defined as in the simulation section.

Figure 3.5. Venn Diagram Comparing the Number of Significant Differentially Methylated
Regions (DMRs) Identified by the SFPCA, FPCA, and M3D Methods in the APL RRBS
data set.

The false discovery rate was controlled at 5% for all analyses. Out of 14,000 CpG
regions selected for testing, SFPCA and FPCA identified 3,987 and 3,897 DMRs,
respectively, whereas M3D identified 2603 DMRs (Figure 3.5). Note that 1225 DMRs
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were identified by all three methods, but there was much more overlap in the SFPCA and
FPCA results than with both methods and M3D. These results align with simulation results
the showed similarity between SFPCA and FPCA with M3D having large type II errors
and identifying fewer DMR overall.

5. CONCLUSION
This study reveals that reduced representation bisulfite sequencing (RRBS) datasets
can be analyzed using higher-order mathematics, using a functional data analysis approach.
Region level differential methylation tests can be formed by using functional principal
components that capture spatial features of methylation profiles. In this work, a smoothed
functional principal component analysis (SFPCA) based on Fourier basis functions was
developed to accurately identify differentially methylated regions (DMRs) between two
conditions (e.g cases and control) with RRBS data. Using a simulation study based on real
data, the SFPCA exhibited higher average true positive rates (TPR) when compared with
FPCA without smoothing and M3D. Since low coverage can prevent statistical significance
and high coverage can be costly to perform, simulations investigated how coverage depth
along with different replicate numbers affected performance of the methods. SFPCA was
substantially robust in relation to both coverage depth and replication maintaining high (>
78%) TPR across all settings. Overall, the SFPCA based on the Fourier basis expansion
method surpassed performance of both the FPCA and M3D approaches in the simulation
based on real data, as it accurately discovered more true differentially methylated regions,
while maintaining a low type I error rate. Although SFPCA and FPCA exhibited similar
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results, SFPCA always slightly surpassed FPCA and both approaches surpassed M3D in
their ability to accurately detect true DMRs.
Even though M3D is sensitive to spatially correlated changes in methylation, it still
does not allow the investigation of the dominant modes of variation in RRBS data.
However, one of the best advantages of FPCA methods is to investigate the dominant
modes of variation in RRBS data using the eigenfunctions of the methylation profile
covariance function. The addition of a roughness penalty on the functional principal
component weights to improve the smoothness appeared to be beneficial when comparing
FPCA with SFPCA. The SFPCA method is superior to other currently used methods
because the SFPCA scores (1) takes into account higher order properties of curve trajectory
shapes when analyzing the methylation profiles and (2) accounts for correlations across all
cytosine sites in the region. Further, the SFPCA statistic provides a region level comparison
of the average SFPCA scores between cases and control groups by reducing information
across multiple sites to a single region level test. The SFPCA approach builds on the
interpretation of next-generation sequencing data by translating high-dimensional DNA
methylation data into a few key factors. This greatly reduces the degrees of freedom in
testing, yet it preserves the majority of the underlying biological signals.
Building on this research, the use of other functional data analysis techniques, (e.g.,
functional linear regression or functional canonical correlation analysis) can now be
investigated. Extending the method to more complex experimental designs with more than
two groups or covariates would be advantageous. Furthermore, although the effectiveness
of SFPCA was investigated using RRBS, it should also work for whole genome studies but
this needs to be more fully explored. Finally, although the predefined regions were defined
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based on CpG density, it is also possible to apply the SFPCA method to regions based on
functional annotation (e.g., CpG islands, CpG shores, and UTRs). Future studies would
determine how the difference in CpG density in annotation regions affect the method
performance.
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4. SUMMARY AND FUTURE WORK

The main purpose of this dissertation is to provide a novel statistical framework for
identifying differentially methylated regions that contribute to biologically meaningful
interpretation of reduced representation bisulfite sequencing (RRBS) data. Specific
methods from functional data analysis (FDA) can be beneficial since they utilize
correlation between neighboring cytosines and capture dominant modes of variation in
methylation trajectories over a region. Testing differentially methylated regions through
functional principal component analysis (FPCA) is described in Section 2. This research
developed an FPCA method based on Fourier and B-spline basis functions that successfully
tested for differentially methylated regions (DMRs) between the case and control groups
in the RRBS data. An empirical comparison of FPCA to the only other similar type of
region level test that explored curve shape differences, M3D1, was made via a simulation
based on real data. FPCA showed a significant increase in true positive rates in comparison
with M3D, as well as considerable robustness with respect to coverage depth and
replications. The FPCA based on the Fourier and B-spline methods both outperformed
M3D as they both accurately detected more DMRs across all simulation settings. FPCAFourier and FPCA-Bspline perform similarly overall, except that FPCA-Fourier had
slightly lower type II errors than FPCA-Bspline when the sequencing depth was 20 reads
and this was reversed for lower degrees of differential methylation for 5 reads. Both
methods maintained a type I error rate below 0.05.
Since the methylation profiles are typically not smooth across a region, this leads
to substantial variability in the estimated functional principal component curves. Thus,
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further improvements to the FPCA method were developed in Section 3 via a smoothed
functional principal component analysis (SFPCA) for detecting differentially methylated
regions. This smoothed FPCA identifies DMRs by combining a goodness-of-fit measure
with a roughness penalty to maintain the advantages of basis expansion. The SFPCA is
used to compare differences within a region in the average SFPCA scores between the
variation of cases and controls. In this study, the SFPCA scores take into account all
information across all CpG sites in a predefined genomic region based on CpG density. In
comparison to the currently available M3D method, the SFPCA technique had
significantly higher true positive rates (TPR) and was robust in relation to coverage depth
and replications, using a simulation study based on real data. The SFPCA method also
showed slight improvements in the TPR when compared to FPCA without smoothing,
indicating that this additional model component was beneficial in capturing an important
aspect of the DNA methylation profile over a region level.
In future research, the SFPCA and FPCA framework could be expanded to
incorporate a test for more complex experimental designs that involve more than two
groups or that include covariates such as age, sex or medical related information.
Furthermore, this technique could be tested where the functional annotation information is
used to define the regions (e.g., CpG islands, CpG shores, UTRs, introns, and exons). An
investigation into how the CpG density within annotation regions differs and will affect
the testing performance will be beneficial to understanding the difference in the two
options. Also the SFPCA and FPCA could be expanded to plants data where the DNA
methylated occurred in three sequence contexts: CG, CHG and CHH (where H=A, T or
C).
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